Orchestra BioMed Holdings, Inc.
OBIO
$4.03
$0.082.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -99.64% | 3,490.82% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -99.64% | 3,490.82% | |||
| Cost of Revenue | -37.25% | 4.08% | |||
| Gross Profit | -99.75% | 3,701.23% | |||
| SG&A Expenses | -12.57% | 2.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.18% | 14.12% | |||
| Operating Income | -426.86% | 133.25% | |||
| Income Before Tax | -431.32% | 129.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -431.32% | 129.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -431.32% | 129.98% | |||
| EBIT | -426.86% | 133.25% | |||
| EBITDA | -421.62% | 133.79% | |||
| EPS Basic | -441.16% | 124.23% | |||
| Normalized Basic EPS | -462.70% | 125.26% | |||
| EPS Diluted | -441.16% | 124.23% | |||
| Normalized Diluted EPS | -462.70% | 125.26% | |||
| Average Basic Shares Outstanding | 1.22% | 18.74% | |||
| Average Diluted Shares Outstanding | 1.22% | 18.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||